This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Javelin Pharmaceuticals, FuelCell Energy: Midday Volume Plays

NEW YORK (TheStreet) -- Javelin Pharmaceuticals (JAV) was one of several stocks trading near $5 moving on above-average volume Thursday as the company's shares slid on merger woes.

Javelin Pharmaceuticals said it has filed a lawsuit against Hospira (HSP) and its subsidiary Discus Acquisition Corp. for a breach of the merger agreement announced in April. Javelin's lawsuit contends that Hospira and Discus breached the merger agreement by failing to accept and pay for shares tendered through May 18.

Late last month, Therabel Pharma N.V., Javelin's European commercial partner, said it was recalling all batches of its injectable pain drug Dyloject from the U.K. market due to quality control problems. Due to the recall, Hospira extended the deadline of the tender offer "based on its determination that all of the conditions to the offer had not been satisfied as of the expiration date of the offer."

Hospira said Thursday it has once again extended the tender offer to purchase Javelin to June 16. The offer had been set to expire earlier Thursday.

Javelin shares were lately tumbling by 23 cents, or 15.1%, to $1.29. Hospira shares were up 0.3% to $52.02. The news prompted increase volume activity in Javelin shares. Volume topped 7.67 million shares, compared to the three-month average daily volume of 1.54 million, according to Yahoo! Finance.

On the other hand, FuelCell Energy (FCEL) was rallying by 46 cents, or 21.6%, to $2.59 after the company said it has received contracts totaling approximately $12.6 million from Pacific Gas and Electric Company for fuel cell power plants to install as utility-owned fuel cells on the campuses of California State University East Bay. Volume topped 2.3 million shares, compared to the 50-day average daily volume of 806,000, according to the Nasdaq.

ZymoGenetics (ZGEN) also traded sharply higher, up 52 cents, or 12.5%, to $4.74, after the company said it has initiated the second part of a Phase II trial for its Hepatitis C treatment PEG-Interferon lambda. Volume topped 886,000 shares, compared to the 50-day average daily volume of 512,000.

Among other decliners on heavy volume, American Capital (ACAS) dropped 14.4% to $4.47 after Stifel Nicolaus cut its rating on the stock to sell from hold, arguing that the probability of bankruptcy has risen significantly. Volume of 29.14 million shares easily outpaced the average daily share volume of 8.34 million.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 +0.97 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs